Key facts
- The paper is a review by Jill S. Goldman (Columbia University Irving Medical Center) and Sonia M. Vallabh (Broad Institute, Massachusetts General Hospital, Prion Alliance), in Genetics in Medicine 24(10):1993-2003, DOI 10.1016/j.gim.2022.06.003, PMID 35819418.
- It states that about 10-15% of prion disease is caused by dominant gain-of-function variants in PRNP.
- It notes that rarity and variable presentation make diagnosis hard and can obscure family history, so families may be unprepared for the genetic implications of a diagnosis.
- It reports that a new prion-detection assay has changed diagnosis in symptomatic people.
- It describes penetrance, age of onset and disease duration as now characterised across PRNP variants in a global cohort.
- It argues the genotype-phenotype link is weaker than once assumed, so "genetic prion disease" may serve providers better than the historical labels CJD, FFI and GSS.
- It says trials of genetically targeted therapies are being planned and that healthy at-risk people may be best placed to benefit, so they need access to counselling and testing.
- Its stated aim is to give providers the information needed to expand genetic counselling for prion disease.
- Vallabh describes the content as covering counselling scenarios for symptomatic patients, at-risk people and family questions, plus resources: testing through the National Prion Disease Pathology Surveillance Center, support from the CJD Foundation, PrionRegistry.org, and educational sites from Prion Alliance and cureffi.org.
- The authors intend to update the paper every few years as the field changes.
- The CJD Foundation page for genetic counsellors names the paper and refers families to its helpline for finding a counsellor.
Timeline
- 2022Published online 12 July 2022.
- 2022Prion Alliance post introducing the guidance, 28 July 2022.
- 2022Printed in Genetics in Medicine volume 24 issue 10, pages 1993-2003.
People
Last checked 1 November 2026